DoD Reconstructive Transplant, Idea Discovery Award | HT942524RTRPIDA

Opportunity Information: Apply for HT942524RTRPIDA

The Department of Defense FY24 Reconstructive Transplant Research Program (RTRP) Idea Discovery Award is a grant opportunity designed to jump-start bold, early-stage ideas in reconstructive transplant research, particularly in vascularized composite allotransplantation (VCA) such as hand or face transplantation. The program is intentionally aimed at high-risk, potentially high-reward projects that are still untested, where the main deliverable is strong, credible data that can serve as a launching pad for larger studies and new research directions. In other words, this award is meant to help researchers prove or disprove a novel concept with enough rigor that the results can realistically support future funding and follow-on investigations.

A central expectation of this mechanism is genuine innovation. Proposed work needs to be clearly new in concept or approach, such as introducing a new paradigm, challenging an existing assumption in the field, or tackling a stubborn problem from an entirely different angle. Projects that mainly extend earlier publications in a straightforward way, or that look like the next logical step of an already-funded or well-established research line, are not considered a fit and are unlikely to be funded. That said, the program does allow applicants to draw inspiration from solid organ transplant advances and bring those ideas into a VCA context, as long as the application explains why testing in VCA is scientifically meaningful. For example, an applicant might justify that VCA has unique immunology, mixed tissue types, distinct rejection patterns, or different functional outcomes, so a concept proven in kidney or heart transplantation could behave differently (or yield new mechanistic insight) when applied to VCA.

Even though the award targets untested ideas, it still requires applicants to ground the work in a clear, testable hypothesis and a solid rationale. The research plan should reflect a thoughtful experimental design, and any chosen model system (if one is used) needs to be appropriate and relevant to VCA. Importantly, preliminary data are required. The intent is not to fund projects that are pure speculation; applicants need to show some supporting evidence, whether preliminary or published, that backs the rationale and suggests the team can complete the proposed work. The balancing act is that the underlying idea should remain meaningfully new and not yet proven.

Applications also need to demonstrate impact by aligning with at least one of the FY24 RTRP Idea Discovery Award focus areas (the specific focus areas are referenced in the announcement but not listed in the excerpt you provided). Applicants are expected to state what concrete outcomes the project will produce, which could include knowledge products (like datasets, mechanistic insights, or validated hypotheses) and/or material products (like tools, assays, model refinements, or enabling methods). Beyond immediate deliverables, the proposal should spell out how this early work could open longer-term benefits for the field and ultimately improve reconstructive transplant science or practice.

Military relevance is a required thread throughout the program. The work should address needs connected to military Service Members or Veterans recovering from traumatic injuries, and it can also include relevance to their families, caregivers, or clinicians, as well as broader public benefit. The announcement encourages collaboration with military clinicians and researchers, and it also strongly supports leveraging Department of Defense or Department of Veterans Affairs (VA) resources where appropriate. Multidisciplinary partnerships across academia, industry, DoD, VA, and other federal agencies are viewed positively because they can provide infrastructure, specialized expertise, and access to unique populations or data sources. If a project depends on access to special databases, samples, or other unique resources, the application must explain how access is already secured at the time of submission and how it will be maintained during the project.

The opportunity also signals a strong interest in advancing womens health research and innovation. The program encourages studies that examine conditions or outcomes that affect women uniquely, disproportionately, or differently than men, including the integration of sex as a biological variable where relevant. Applicants proposing such work are expected to connect their anticipated findings to meaningful improvements in womens health outcomes or to expanding what is known about reconstructive transplant as it relates to women.

On research quality expectations, the award emphasizes rigorous experimental design and transparent reporting to improve reproducibility and translational value. The announcement points applicants to widely recognized best practices, including principles like randomization, blinding, sample-size estimation, and clear data handling procedures. While the cited guidance is written with preclinical research in mind, the program stresses that the underlying methodological standards apply broadly and are aligned with best practices seen in clinical research as well.

Human research is allowed only within strict limits, and clinical trials are not permitted under this award. Because the Idea Discovery Award is meant for preliminary investigations, projects involving human subjects or human anatomical substances are only allowed if they qualify as exempt under 32 CFR 219.104(d) or are eligible for expedited review under the applicable regulations (including 32 CFR 219.110 or 21 CFR 56.110). Any study that does not qualify for exempt status or expedited review will be administratively withdrawn, meaning it will not move forward for funding. The announcement draws an important distinction between clinical trials and clinical research: observational clinical research can be allowed, including studies using human data or specimens, diagnostic or detection studies like biomarker or imaging work, epidemiologic or behavioral studies, and outcomes or health services research, as long as the project is not prospectively assigning people to an intervention to measure safety or efficacy outcomes. The program also clarifies that certain in vitro studies using unlinked human specimens may fall outside the definition of clinical research if they meet specific exemption requirements.

Administratively, awards are made as grants under 31 USC 6304. The budget guidance sets an anticipated total cost cap of $500,000 for the entire period of performance per Idea Discovery Award. At the program level, the DoD expects to allocate about $2.5 million total to fund roughly five awards, though actual funding depends on federal funds availability, application volume, and the outcomes of peer and programmatic review. Awards supported by FY24 funds are expected to be made no later than September 30, 2025, and the FY24 funds are anticipated to remain available for use until September 30, 2030 (reflecting the limited period during which those federal funds can be obligated and expended).

Finally, award recipients should be prepared for program engagement during the project. The RTRP holds annual virtual In-Progress Review meetings where selected performers may be invited to present updates to the programmatic panel and program staff, which is part of how the program monitors progress and keeps projects aligned with RTRP goals.

Key listing details from the opportunity include: Funding Opportunity Number HT942524RTRPIDA; Agency Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA); CFDA 12.420; category Discretionary; instrument type Grant; eligible applicants listed as unrestricted; original closing date October 23, 2024; and an expected number of awards of about five.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Reconstructive Transplant, Idea Discovery Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-27.
• Applicants must submit their applications by 2024-10-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524RTRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: